All In MedTech

Device Trial Radar · NCT04656678

Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer

A Study to Evaluate the Safety and Efficacy of Focal US Guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Low to Intermediate Risk Prostate Cancer and Focal Salvage Cryotherapy for Recurrent Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 25, 2020

Primary completion

Oct 30, 2028

Study completion Oct 30, 2028

Sponsor

Lead sponsor
Northwell HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Philips Healthcare
First posted
Dec 7, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of using ultrasound only during the cryoablation of the prostate. The software application may aid doctors in locating a prior biopsy proven cancer location from the UroNav biopsy that patients previously had and then use that information to guide the treatment.

Conditions

  • Prostate Cancer
  • Prostate Disease
  • Locally Recurrent Prostate Cancer

Interventions

  • Cryo-ablation Using DynaCAD / UroNAV preplanning / guidanceDevice

    Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of safety of the DynaCAD /UroNAV ablation planning and guidance system aided cryo-ablation in the treatment of low-intermediate risk, localized (organ confined) prostate cancer tumors.Time frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Smith Institute for Urology

    Lake Success, New York · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.